MURA MURAL ONCOLOGY PUB LTD CO

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at . A replay of the webcast will be archived and available following the event.

About Mural Oncology

Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. Our lead candidate, nemvaleukin alfa, is currently in potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma reading out in late Q1/early Q2 and Q2 of 2025, respectively. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at  and follow us on  and . 

Contact:

Katie Sullivan



EN
18/02/2025

Underlying

MURAMURAL ONCOLOGY PUB LTD CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MURAL ONCOLOGY PUB LTD CO

 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Number of Relevant Securities in Issue

Mural Oncology Announces Number of Relevant Securities in Issue WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, (“Mural”) confirms that, as of the close of business on May 1, 2025, the issued share capital of Mural was 17,268,881 ordinary shares with par value US$0.01 each (the “Ordinary Shares”).   In addition, as of the close of business on March 31, 2025, there were outsta...

May 19, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

FORM 8.1(a) & (b) - Mural Oncology plc

FORM 8.1(a) & (b) - Mural Oncology plc Ap9 FORM 8.1(a) & (b)(Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.      KEY INFORMATION (a)   Full name of discloser:Mural Oncology plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c)   Na...

April 30, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc 23-Apr-2025 / 14:38 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION             Full name of discloser The Vanguard Group, Inc.           Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nomin...

April 23, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc 17-Apr-2025 / 14:20 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION             Full name of discloser The Vanguard Group, Inc.           Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nomin...

April 17, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Plans to Explore Strategic Alternatives

Mural Oncology Announces Plans to Explore Strategic Alternatives Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MURA), a clinical-stage immuno-oncology company, today announced that following review of dat...

April 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch